Magis-Pharma
ActiveSummary
The computed 12-month bankruptcy probability of Magis-Pharma is 1.6% (moderate). The annual accounts of Magis-Pharma for financial year 2025 show a net loss of 60% of the equity at the start of that year. The 2025 annual accounts show equity of €247,993 and a net result of -€374,469. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 9% of 6,136 sector peers (NACE 46, financial year 2025). The company has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Connections & network
7 connected companiesThis company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
Curavex
Shared corporate director
→
DBC Operations
Shared corporate director
→
Fraver
Shared corporate director
→
GOD'S PLAN
Shared corporate director
→
Show 3 more companies with a shared director
isomasters
Shared corporate director
→
PARCHIM
Shared corporate director
→
TENDOTOOLS
Shared corporate director
→